Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that Aurgalys, an equity research firm dedicated to life sciences, initiated the coverage of the company.
Their first financial analysis note, entitled «Quantum Genomics could revolutionize the hypertension market», is available on the website of Quantum Genomics, Investors section, and on Aurgalys website (www.aurgalys.com).
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2014/11/QGC_CP_AURGALYS_05112014_UK.pdf” size=”small” color=”red”]